Patents Represented by Attorney Michael D. Alexander
  • Patent number: 5783589
    Abstract: 4-R.sup.4 -R.sup.5 -2-Saccharinylmethyl aryl and aryloxy acetates, useful in the treatment of degenerative diseases, are prepared by reacting a 4-R.sup.4 -R.sup.5 -2-halomethylsaccharin with an aryl or aryloxyacetic acid in the presence of an acid-acceptor.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: July 21, 1998
    Assignee: Sanofi
    Inventors: Lee Hamilton Latimer, Richard Paul Dunlap
  • Patent number: 5776987
    Abstract: A pharmaceutical suspension formulation comprising 0.1 to 40% by weight ##STR1## as the active ingredient; 0.1 to 40% by weight Transcutol; 0.1-99% by weight starch; 0-40% by weight polyethylene glycol, NaOH and water,wherein the mole equivalents of NaOH per mole equivalent of active ingredient is from 0.5 to 1.5 is particularly useful for filling hard gelatin capsules.
    Type: Grant
    Filed: March 3, 1997
    Date of Patent: July 7, 1998
    Assignee: Sanofi Pharmaceuticals, Inc.
    Inventors: William L. Rocco, Sharon M. Laughlin
  • Patent number: 5773456
    Abstract: Compounds having the structural formula ##STR1## wherein L is N, O or SO.sub.n wherein n is 0, 1 or 2;L--R.sup.1 is a leaving group, H--L--R.sup.1 is the conjugate acid thereof and, when L is N, H--L--R.sup.1 has a pK.sub.a value less than or equal to 6, when L is O, H--L--R.sup.1 has a pK.sub.a value less than or equal to to 8, and when L is SO.sub.n, H--L--R.sup.1 has a pK.sub.a value less than or equal to 5;R.sup.2 is primary or secondary alkyl of two to four carbon atoms, primary alkylamino of one to three carbon atoms, primary alkylmethylamino of two to four carbon atoms, diethylamino or primary alkoxy of one to three carbon atoms; andR.sup.
    Type: Grant
    Filed: September 25, 1996
    Date of Patent: June 30, 1998
    Assignee: Sanofi
    Inventors: Richard Paul Dunlap, Albert Joseph Mura, Dennis John Hlasta, Ranjit Chimanlal Desai, Lee Hamilton Latimer
  • Patent number: 5763461
    Abstract: Compounds of the formula ##STR1## wherein Pyr is chosen from the group consisting of pyridyl, pyrazyl, pyrimidyl, quinolyl, indolyl and 7-azaindolyl or any of these substituted with one or two substitutents chosen from alkyl, alkoxy, hydroxy, halo, cyano, nitro, hydroxyalkyl, alkoxyalkyl, alkanoyl, fluoroalkyl or the N-oxide of any of these;Y is an alkylene bridge of 3-9 carbon atoms;R.sub.1 and R.sub.2 are each independently chosen from hydrogen, halo, alkyl, alkenyl, amino, alkylthio, hydroxy, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfinylaikyl, alkylsulfonylalkyl, alkoxy, nitro, carboxy, alkoxycarbonyl, dialkylaminoalkyl, alkylaminoalkyl, aminoalkyl, difluoromethyl, trifluoromethyl or cyano;R.sub.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: June 9, 1998
    Assignee: Sanofi
    Inventors: David J. Aldous, Thomas R. Bailey, Guy Dominic Diana, Gee-Hong Kuo, Theodore J. Nitz
  • Patent number: 5760056
    Abstract: A pharmaceutical formulation comprising ##STR1## as the active ingredient, polyethylene glycol,NaOH, andwater, wherein the mole equivalents of NaOH per mole equivalent of active ingredient is at least about 1.1, is suitable for soft gelatin capsule filling.
    Type: Grant
    Filed: March 3, 1997
    Date of Patent: June 2, 1998
    Assignee: Sanofi Pharmaceuticals, Inc.
    Inventors: Sharon M. Laughlin, Nancy M. Franson
  • Patent number: 5750527
    Abstract: Described herein are compound of the formula: ##STR1## wherein: Thi is thiadiazolyl or substituted thiadiazolyl;Y is alkylene bridge of 3-9 carbon atoms;R.sub.1 and R.sub.2 are each independently chosen from hydrogen, halo, alkyl, alkenyl, amino, alkylthio, hydroxy, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfinyl alkyl, alkylsulfonylalkyl, alkoxy, nitro, carboxy, alkoxycarbonyl, dialkylaminoalkyl, alkylaminoalkyl, aminoalkyl, difluoromethyl, trifluoromethyl, or cyano;R.sub.3 is a heterocyclyl chosen from pyrimidinyl, pyrazinyl, or pyridazinyl;or a pharmaceutically acceptable salt thereof which are effective antipicornaviral agents.
    Type: Grant
    Filed: May 27, 1997
    Date of Patent: May 12, 1998
    Assignee: Sanofi
    Inventors: David J. Aldous, Thomas R. Bailey, Guy Dominic Diana, Theodore J. Nitz
  • Patent number: 5750550
    Abstract: 2-(Pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxides, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.
    Type: Grant
    Filed: September 15, 1995
    Date of Patent: May 12, 1998
    Assignee: Sanofi
    Inventors: Michael A. Eissenstat, Gee-Hong Kuo, Ranjit C. Desai, Dennis J. Hlasta, John J. Court
  • Patent number: 5750546
    Abstract: 2-(2,3,5,6-Tetrafluoro-4-pyridyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.
    Type: Grant
    Filed: December 2, 1994
    Date of Patent: May 12, 1998
    Assignee: Sanofi Winthrop, Inc.
    Inventor: Ranjit Chimanlal Desai
  • Patent number: 5744471
    Abstract: The present invention relates to compounds, pharmaceutical compositions and methods of using compounds of formula (I) in the treatment and/or prevention of certain diseases or conditions. In formula (I), A is chosen from ortho substituted aryl or heteroaryl species, X is chosen from --OH, --SH, NHR and R.sup.1 or R.sup.2 is chosen from --(CH.sub.2).sub.n L wherein L may be selected from a variety of substituents including aryl, heteroaryl and heterocyclic groups. The compounds are useful in treating and/or preventing neurological disorders associated with excitatory amino acids.
    Type: Grant
    Filed: April 17, 1996
    Date of Patent: April 28, 1998
    Assignee: Zeneca Limited
    Inventors: Thomas Michael Bare, Timothy Wayne Davenport, James Roy Empfield, Jeffrey Alan McKinney, Richard Bruce Sparks
  • Patent number: 5739133
    Abstract: The present invention relates to pyridazino?4,5-b!quinolines, and pharmaceutically useful salts thereof, which are excitatory amino acid antagonists and which are useful when such antagonism is desired such as in the treatment of neurological disorders. The invention further provides pharmaceutical compositions containing pyridazino?4,5-b!quinolines as active ingredient, and methods for the treatment of neurological disorders.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: April 14, 1998
    Assignee: Zeneca Limited
    Inventors: Thomas Michael Bare, Richard Bruce Sparks
  • Patent number: 5736548
    Abstract: 6-Aryl pyrazolo?3,4-d!pyrimidin-4-one derivatives, pharmaceutical compositions containing them and methods for effecting c-GMP-phosphodiesterase inhibition and for treating heart failure and/or hypertension.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: April 7, 1998
    Assignee: Sanofi
    Inventors: Edward R. Bacon, Baldev Singh
  • Patent number: 5733910
    Abstract: The present invention relates to pyridazino?4,5-b!quinolines, and pharmaceutically useful salts thereof, which are excitatory amino acid antagonists and which are useful when such antagonism is desired such as in the treatment of neurological disorders. The invention further provides pharmaceutical compositions containing pyridazino?4,5-b!quinolines as active ingredient, and methods for the treatment of neurological disorders.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: March 31, 1998
    Assignee: Imperial Chemical Industries PLC
    Inventors: Thomas Michael Bare, Richard Bruce Sparks
  • Patent number: 5721261
    Abstract: Compounds of the formula ##STR1## wherein Azo is alkyltetrazolyl or is chosen from the group consisting of oxadiazolyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, triazinyl, thiazolyl, isothiazolyl or any of these substituted with a member of the group consisting of alkyl, alkylthio, alkoxy, hydroxy, halo, cyano, nitro, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkanoyl, fluoroalkyl or the N-oxide of any of the preceding;Y is an alkylene bridge of 3-9 carbon atoms;R.sub.1 and R.sub.2 are each individually chosen from hydrogen, halo, alkyl, alkenyl, amino, alkylthio, hydroxy, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkoxy, nitro, carboxy, alkoxycarbonyl, dialkylaminoalkyl, alkylaminoalkyl, aminoalkyl, difluoromethyl, trifluoromethyl or cyano;R.sub.
    Type: Grant
    Filed: August 2, 1996
    Date of Patent: February 24, 1998
    Assignee: Sanofi Pharmaceuticals, Inc.
    Inventors: David J. Aldous, Thomas R. Bailey, Guy Dominic Diana, Theodore J. Nitz, Gee-Hong Kuo
  • Patent number: 5719166
    Abstract: Compounds of formula I, and pharmaceutically acceptable salts thereof, useful in the treatment of neuropsychiatric disorders such as psychoses; pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable diluent or carrier; and methods of treating neuropsychiatric disorders comprising administering to a mammal (including man) in need of such treatment an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 15, 1996
    Date of Patent: February 17, 1998
    Assignee: Imperial Chemical Industries PLC
    Inventors: Robert Toms Jacobs, Cyrus John Ohnmacht, Diane Amy Trainor
  • Patent number: 5712272
    Abstract: Benz?b!azepine compounds, pharmaceutical compositions containing them and methods for the treatment of neurological disorders utilizing them.
    Type: Grant
    Filed: January 13, 1997
    Date of Patent: January 27, 1998
    Assignee: Zeneca Limited
    Inventors: Gregory David Harris, Marc Jerome Chapdelaine, Paul Francis Jackson
  • Patent number: 5681840
    Abstract: Compounds of formula I or I', ##STR1## wherein X and Y are independently selected from hydrogen, halo, and (1-6C)alkoxy;R.sup.1 is selected from(A) (1-6C)alkyl;(B) phenyl and naphthyl or substituted versions thereof;(C) phenyl(1-3C)alkyl and naphthyl(1-3C)alkyl;(D) five- and six-membered heteroaryl rings;(E) heteroaryl(1-3C)alkyl and pharmaceutically acceptable salts thereof, useful in the treatment of neuropsychiatric disorders such as psychoses; pharmaceutical compositions comprising a compound of formula I or I' and a pharmaceutically acceptable diluent or carrier; and methods of treating neuropsychiatric disorders comprising administering to a mammal (including man) in need of such treatment an effective amount of a compound of formula I or I', or a pharmaceutically acceptable salt thereof are claimed. The invention also relates to novel processes for producing enantiomeric methanoanthracenyl sulfoxides.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: October 28, 1997
    Assignee: Zeneca Limited
    Inventors: Robert Toms Jacobs, Michael Thaddeus Klimas, Cyrus John Ohnmacht, Marc Ornal Terpko
  • Patent number: 5656626
    Abstract: Antagonists at the NMDA receptor complex which are benz[b]azepines having a hydroxy, alkoxy or amino substituent at the 3-position and a 4-position alkenyl, alkynyl, aryl or heteroaryl substituent for treatment of stroke and/or other neurodegenerative disorders.
    Type: Grant
    Filed: October 19, 1995
    Date of Patent: August 12, 1997
    Assignee: Zeneca Limited
    Inventors: Marc Jerome Chapdelaine, Timothy W. Davenport, Laura E. Garcia-Davenport, Paul Francis Jackson, Jeffrey A. McKinney, Charles D. McLaren
  • Patent number: 5654295
    Abstract: Benz[b]azepine compounds, pharmaceutical compositions containing them and methods for the treatment of neurological disorders utilizing them.
    Type: Grant
    Filed: September 7, 1995
    Date of Patent: August 5, 1997
    Assignee: Zeneca Limited
    Inventors: Gregory David Harris, Marc Jerome Chapdelaine, Paul Francis Jackson
  • Patent number: 5652239
    Abstract: The present invention relates to pyridazino[4,5-b]indoles, and pharmaceutically useful salts thereof, which are excitatory amino acid antagonists and which are useful when such antagonism is desired such as in the treatment of neurological disorders. The invention further provides pharmaceutical compositions containing pyridazino[4,5-b]indoles as active ingredient, and methods for the treatment of neurological disorders.
    Type: Grant
    Filed: October 19, 1995
    Date of Patent: July 29, 1997
    Assignee: Imperial Chemical Company
    Inventors: Thomas Michael Bare, James Franklin Resch, Paul Francis Jackson
  • Patent number: 5607933
    Abstract: 2--R.sub.2 --R.sub.4 -substituted-3--R.sub.3 --CO--1--[(C-attached-N-heteryl)-(Alk).sub.n ]--1H-indoles useful as analgesic, anti-rheumatic, anti-inflammatory or anti-glaucoma agents.
    Type: Grant
    Filed: March 16, 1994
    Date of Patent: March 4, 1997
    Assignee: Sterling Winthrop Inc.
    Inventors: Thomas E. D'Ambra, Edward R. Bacon, Malcolm R. Bell, Susan J. Ward